| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Nicola Petrosillo | Q56395236 |
| Evelina Tacconelli | Q87722568 | ||
| Maria Adriana Cataldo | Q87723103 | ||
| Federico Pea | Q38544304 | ||
| P2093 | author name string | Elisabetta Grilli | |
| P2860 | cites work | Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion | Q42627607 |
| Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy | Q43278382 | ||
| Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility | Q43433837 | ||
| Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections | Q43823469 | ||
| Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study | Q44903352 | ||
| High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion | Q44991015 | ||
| Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections | Q45127594 | ||
| Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides | Q46691587 | ||
| Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? | Q46728126 | ||
| Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies | Q46728767 | ||
| Monitoring of vancomycin serum levels for the treatment of staphylococcal infections | Q46929797 | ||
| Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. | Q54149026 | ||
| Randomized, controlled trials, observational studies, and the hierarchy of research designs | Q24670544 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Operating characteristics of a rank correlation test for publication bias | Q27860653 | ||
| Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis | Q33387451 | ||
| Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease | Q33776590 | ||
| Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection | Q33979426 | ||
| Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study | Q33982863 | ||
| Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children | Q34157657 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists | Q34910366 | ||
| Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials | Q34923394 | ||
| Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients | Q34991274 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? | Q37211603 | ||
| Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials | Q37630016 | ||
| Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis | Q37637758 | ||
| Meta-analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections | Q37704378 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| vancomycin | Q424027 | ||
| meta-analysis | Q815382 | ||
| gram-positive bacteria | Q857288 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 17-24 | |
| P577 | publication date | 2011-10-25 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis | |
| P478 | volume | 67 |
| Q46731557 | A prospective trial on the use of trough concentration versus area under the curve (AUC) to determine therapeutic vancomycin dosing |
| Q40626028 | A protocol for developing a clinical practice guideline for therapeutic drug monitoring of vancomycin |
| Q40104555 | A specially tailored vancomycin continuous infusion regimen for renally impaired critically ill patients |
| Q49142591 | A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals |
| Q60952841 | Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital |
| Q64270497 | Acute kidney injury during daptomycin versus vancomycin treatment in cardiovascular critically ill patients: a propensity score matched analysis |
| Q39375881 | Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals |
| Q90216660 | Administration of Vancomycin at High Doses in Patients with Post Neurosurgical Meningitis: A Comprehensive Comparison between Continuous Infusion and Intermittent Infusion |
| Q37544400 | Are vancomycin trough concentrations adequate for optimal dosing? |
| Q39044128 | Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC? |
| Q28534516 | Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis |
| Q38138835 | Clinical implications of antibiotic pharmacokinetic principles in the critically ill. |
| Q38100704 | Clinical pharmacokinetics of antibacterials in cerebrospinal fluid. |
| Q40979549 | Comparison of intermittent versus continuous vancomycin infusion for the treatment of late-onset sepsis in preterm infants |
| Q91709783 | Continuous Infusion Vancomycin in Pediatric Patients: A Critical Review of the Evidence |
| Q42432137 | Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin? |
| Q38882052 | Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients |
| Q34777837 | Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram |
| Q47276911 | Delivering precision antimicrobial therapy through closed-loop control systems |
| Q51047130 | Design and prospective validation of a dosing instrument for continuous infusion of vancomycin: a within-population approach. |
| Q37712974 | Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations |
| Q44770615 | Development of acute kidney injury during continuous infusion of vancomycin in septic patients. |
| Q46100350 | Difference in nephrotoxicity of vancomycin administered once daily and twice daily in rats |
| Q97535932 | Effect of Vancomycin Loading Doses on the Attainment of Target Trough Concentrations in Hospitalized Children |
| Q38938708 | Establishment of an AUC0-24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia |
| Q35676081 | Evaluation of a protocol for vancomycin administration in critically patients with and without kidney dysfunction |
| Q28539717 | Guidelines for therapeutic drug monitoring of vancomycin: a systematic review |
| Q34894900 | How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? |
| Q54699954 | How to optimize the evaluation and use of antibiotics in neonates. |
| Q38569678 | How to use vancomycin optimally in neonates: remaining questions |
| Q37220711 | Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America |
| Q43156951 | Influence of vancomycin infusion methods on endothelial cell toxicity |
| Q30245399 | Managing infective endocarditis in the elderly: new issues for an old disease. |
| Q88924840 | Methicillin-resistant Staphylococcus aureus |
| Q37120168 | New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients |
| Q28069334 | Optimizing the Clinical Use of Vancomycin |
| Q47634145 | Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia. |
| Q90426419 | Prospective Cohort Study of the Tolerability of Prosthetic Joint Infection Empirical Antimicrobial Therapy |
| Q58613760 | Protocol for a randomised controlled trial of continuous infusions of vancomycin to improve the attainment of target vancomycin levels in young infants: The VANC trial |
| Q33949459 | Questioning the accuracy of trough concentrations as surrogates for area under the curve in determining vancomycin safety. |
| Q38081494 | Rescue therapy of difficult-to-treat indwelling central venous catheter-related bacteremias in cancer patients: a review for practical purposes |
| Q38079526 | Review of continuous-infusion vancomycin |
| Q38687487 | The Nephrotoxicity of Vancomycin |
| Q38417173 | The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion |
| Q38068293 | The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. |
| Q36571794 | Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling |
| Q53767442 | Treatment of severe MRSA infections: current practice and further development. |
| Q38246118 | Treatment option for sepsis in children in the era of antibiotic resistance |
| Q48089081 | Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice |
| Q42282104 | Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring |
| Q38818376 | Vancomycin dosing nomograms targeting high serum trough levels in different populations: pros and cons |
| Q38258649 | Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. |
| Q34636783 | Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study |
| Q45383308 | Vancomycin use in neonates and children: evidence-based practice is needed |
| Q38249103 | Vancomycin-associated renal dysfunction: where are we now? |
| Q37992997 | Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review |
| Q38542797 | Vancomycin: the tale of the vanquisher and the pyrrhic victory. |
| Q88208602 | [Prevention of acute kidney injury in critically ill patients : Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI] |
Search more.